Show Summary Details
Page of



Richard W. Keen

Page of

PRINTED FROM OXFORD MEDICINE ONLINE ( © Oxford University Press, 2021. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 28 January 2021

Bisphosphonates are potent inhibitors of bone resorption.

Bisphosphonates are the first-line treatment for the majority of patients with osteoporosis.

Oral bisphosphonates have a complex dosing schedule, and this has led to the development of intermittent dosing (weekly and monthly) in an attempt to improve compliance.

Intravenous administration of bisphosphonates offers an alternative to patients with a history of upper gastrointestinal disease, malabsorption, or where compliance with oral therapy is poor.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.